First Patient Enrolled in Second Phase III Clinical Trial of Urocidin

Endo Pharmaceuticals ENDP and Bioniche Life Sciences Inc. (TSX and ASX: BNC), today announced enrollment of the first patient in the second Phase III clinical trial of Urocidin™. The trial is a randomized, active-controlled, open-label, multi-center study with a blinded endpoint assessment designed to compare Urocidin™ with mitomycin C in the intravesical treatment of patients with BCG recurrent or refractory non-muscle-invasive bladder cancer. It is estimated that 450 patients will be enrolled for this new trial at approximately 120 clinical sites worldwide. Summary details of the study protocol are now publicly available via the U.S. National Institutes of Health (NIH) clinical trial registration service at http://www.clinicaltrials.gov.